Firefly to offer NeuroSigma's non-drug ADHD device to clinicians

Firefly Neuroscience and NeuroSigma have partnered to bring Monarch eTNS System for paediatric ADHD to clinicians. The collaboration pairs Firefly's AI-powered brain-assessment platform with NeuroSigma's FDA-cleared, non-medication device for children with ADHD. The partnership integrates NeuroSigma’s non-drug ADHD device with Firefly’s digital brain-mapping clinician network. Credit: PeopleImages/Shutterstock.com. Firefly Neuroscience has struck a partnership with bioelectronic device maker NeuroSigma to broaden clinician reach for the latter’s Monarch eTNS System through its Evoke customer base in the US. The deal is intended to address two recognised gaps in paediatric attention-deficit/hyperactivity disorder (ADHD) care. These are the need for objective data on brain…

Source: Medical Device Network